Actively Recruiting
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Led by Danish Lung Cancer Group · Updated on 2023-09-11
151
Participants Needed
1
Research Sites
422 weeks
Total Duration
On this page
Sponsors
D
Danish Lung Cancer Group
Lead Sponsor
O
Odense University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment. The aim is to study the efficiency as well as the safety of a new treatment option of heterogeneously hypofractionated radiotherapy for patients with locally advanced NSCLC who are not candidates for standard, high-dose chemoradiotherapy, either due to excessive irradiation of normal tissue (defined as category A patients) or due to fragility of the patient (category B patients).
CONDITIONS
Official Title
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed locally advanced, inoperable NSCLC
- Age 18 years or older
- Signed informed consent
- Performance status 0 to 2
- Able to comply with study and follow-up procedures
- Fertile women must have a negative pregnancy test
- Fertile men and women must use effective contraception during treatment and for one month after
- Fertile women must use specified contraceptive methods such as the pill, spiral, depot injection, subdermal implant, hormonal vaginal ring, or transdermal patch
You will not qualify if you...
- Prior radiotherapy to the thorax unless there is no significant overlap with current treatment areas
- Dose plan that does not meet protocol planning criteria
- Uncontrolled metastatic disease
- Other active malignant diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Aarhus University Hospital
Aarhus, Denmark, 8000
Actively Recruiting
Research Team
A
Azza A Khalil, MD, PhD
CONTACT
M
Marianne M Knap, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here